Chondroitin Sulfate A (Structum) In
Osteoarthritis A. Masounabe-Puyanne Societe U.R.P.A.C.,
Objective: To evaluate the
efficacy of Structum.
Methods: 120 patients with
osteoarthritis of the hip and knee were treated for 3 months.
This was followed by a 2-month period without treatment in order
to study the residual effect. The study was multicenter, randomized,
double-blind, controlled trial vs placebo, with parallel groups.
The consumption of nonsteroidal anti-inflammatory drugs (NSAIDs)
(expressed in terms of mg equivalent of diclofenac) was selected
as the principal parameter.
Results: After 3 months of
treatment, NSAIDs consumption had significantly decreased in patients
treated with Structum (four capsules/day), and this decrease persisted
during the 2-month monitoring period without treatment. In the
other parameters studied—measurement of pain by a visual analog
scale, Lequesne's functional pain index, and the global assessment
by both patient and physician—all showed the same significant
tendency. Safety was excellent and no withdrawals from the study
were necessary. Chondroitin sulfate A (Structum) therefore clearly
appears to be of use in the symptomatic treatment of osteoarthritis:
it has a slow action and is NSAID-sparing. Since it has a residual
effect, it could be prescribed as sequential therapy.